Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Mar 27, 2025
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Purchase
Common Stock
2025-03-25$0.69/sh+100,000$69,250→ 480,123 total
Footnotes (1)
- [F1]The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).